After achieving the holy grail of a big pharma buyout, what’s next for the biotech left behind? If Biohaven is anything to go by, the answer is: assemble a new pipeline of projects that do not seem to have much in common.
The company’s chief executive officer, Vlad Coric, tells Evaluate Vantage there is a method to Biohaven’s apparently scattergun approach, however. “We want to be able to make an improvement on de-risked mechanisms,” he says of the firm’s “fast-follower” strategy.
Copyright © 2023,